Cargando…

Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD

Several potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus have been identified. However, antibody-dependent enhancement (ADE) has not been comprehensively studied for SARS-CoV-2, and the relationship between enhancing versus neutralizing activi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yunjiao, Liu, Zezhong, Li, Shibo, Xu, Wei, Zhang, Qianqian, Silva, Israel T., Li, Cheng, Wu, Yanling, Jiang, Qingling, Liu, Zhenmi, Wang, Qiujing, Guo, Yu, Wu, Jianbo, Gu, Chengjian, Cai, Xia, Qu, Di, Mayer, Christian T., Wang, Xiangxi, Jiang, Shibo, Ying, Tianlei, Yuan, Zhenghong, Xie, Youhua, Wen, Yumei, Lu, Lu, Wang, Qiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802522/ https://www.ncbi.nlm.nih.gov/pubmed/33485405 http://dx.doi.org/10.1016/j.celrep.2021.108699

Ejemplares similares

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
por: Liu, Zezhong, et al.
Publicado: (2020)

A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells
por: Wang, Xinling, et al.
Publicado: (2022)

An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
por: Liu, Zezhong, et al.
Publicado: (2021)

Single-Domain Antibodies As Therapeutics against Human Viral Diseases
por: Wu, Yanling, et al.
Publicado: (2017)

In-Depth Analysis of Human Neonatal and Adult IgM Antibody Repertoires
por: Hong, Binbin, et al.
Publicado: (2018)

Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection
por: Wang, Xinling, et al.
Publicado: (2021)

The putative mechanism of lymphopenia in COVID-19 patients
por: Wang, Xinling, et al.
Publicado: (2022)

Up or down: where comes Omicron?
por: Liu, Zezhong, et al.
Publicado: (2022)

Application of “B+1” heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus vaccines
por: Liu, Zezhong, et al.
Publicado: (2023)

A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates
por: Liu, Zezhong, et al.
Publicado: (2023)

Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD
por: Wang, Cong, et al.
Publicado: (2019)

Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS)
por: Lu, Lu, et al.
Publicado: (2015)

A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome
por: Jiang, Shibo, et al.
Publicado: (2020)

Identification of Human Single-Domain Antibodies against SARS-CoV-2
por: Wu, Yanling, et al.
Publicado: (2020)

Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion
por: Wang, Xinling, et al.
Publicado: (2020)

RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion
por: Wang, Xinling, et al.
Publicado: (2020)

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
por: Tai, Wanbo, et al.
Publicado: (2020)

Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection
por: Du, Lanying, et al.
Publicado: (2008)

The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2
por: Li, Cheng, et al.
Publicado: (2021)

Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections
por: Ying, Tianlei, et al.
Publicado: (2015)

Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population
por: Yi, Zhigang, et al.
Publicado: (2020)

Double insult: flu bug enhances SARS-CoV-2 infectivity
por: Su, Shan, et al.
Publicado: (2021)

High-throughput screening of mutations affecting SARS-CoV-2 spike functions
por: Xia, Shuai, et al.
Publicado: (2023)

Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
por: Zhang, Qianqian, et al.
Publicado: (2021)

Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III
por: Wu, Yanling, et al.
Publicado: (2017)

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
por: Tian, Xiaolong, et al.
Publicado: (2020)

Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells
por: Su, Xiaojie, et al.
Publicado: (2020)

Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection
por: Liu, Zezhong, et al.
Publicado: (2020)

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
por: Xia, Shuai, et al.
Publicado: (2020)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

Cross-reactive antibody response to Monkeypox virus surface proteins in a small proportion of individuals with and without Chinese smallpox vaccination history
por: Xia, Anqi, et al.
Publicado: (2023)

Renaming the SARS‐CoV‐2 Omicron sublineages as SARS‐CoV‐3 is contrary to nomenclature standards based on evolutionary and serological evidence
por: Qi, Zhongtian, et al.
Publicado: (2022)

Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy
por: Ouyang, Yabo, et al.
Publicado: (2017)

A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases
por: Zhou, Jie, et al.
Publicado: (2022)

An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene
por: Sun, Zhiwu, et al.
Publicado: (2016)

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
por: Wang, Xinling, et al.
Publicado: (2023)

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein
por: Xia, Shuai, et al.
Publicado: (2014)

A Human DPP4-Knockin Mouse’s Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV
por: Fan, Changfa, et al.
Publicado: (2018)

Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4
por: Xia, Shuai, et al.
Publicado: (2019)

The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin
por: Xia, Shuai, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6tpsfhj9goj682fbve0714u0gm